Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of subcutaneous amivantamab-based regimens in advanced or metastatic solid tumors including EGFR-mutated non-small cell lung cancer
2023-505065-91-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label trial of amivantamab in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (8 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoint: ORR (INV). Planned start Jan 2023; status: authorised.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-505065-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505065-91-00.